NeoGenomics, Definiens to develop novel assays, 6/17
June 2017—NeoGenomics and Definiens have expanded their alliance to develop and automate the analysis of new biomarker assays for clinical trials and routine clinical testing.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
IHC imaging and analysis system, 6/17
June 2017—Applied Spectral Imaging introduced its HiPath imaging and analysis system, which provides computer-assisted PD-L1 interpretation for research use.
CLSI phlebotomy documents, 6/17
June 2017—The Clinical and Laboratory Standards Institute has published two new phlebotomy documents, “Collection of Diagnostic Venous Blood Specimens (GP41-Ed7)” and “Essential Elements of a Phlebotomy Training Program (GP48-Ed1).”
Circulating cell-free DNA isolation kit, 6/17
June 2017—MagBio Genomics launched its cfKapture 21 kit, a circulating cell-free DNA isolation kit that includes a proprietary reagent designed to prevent post-separation degradation of plasma and ccfDNA fragments for up to 21 days at room temperature. This feature allows laboratories to safely transport and process samples in a longer time frame without the need for extensive cold chain.
FDA clearance for Alere Reader platform, 6/17
June 2017—Alere announced that its Alere Reader, a diagnostic platform with objective result interpretation and connectivity capabilities that can be used to evaluate a variety of lateral flow immunoassay formats and that can be used in point-of-care and laboratory settings, received FDA 510(k) clearance.
ArcherDx, HeliTec strategic partnership, 6/17
June 2017—ArcherDx and precision medicine company HeliTec (Shenzhen, China) announced a strategic partnership to advance NGS-based cancer diagnostic development in China. The partnership will entail co-developing and cross-licensing NGS-based technologies with the goal of registering oncology diagnostic kits with the Chinese Food and Drug Administration.
Drugs of abuse screening reagents, 6/17
June 2017—MedTest announced the commercial launch of urine drugs of abuse screening reagents on the Mindray BA-800M chemistry analyzer for use in clinical laboratories in the United States.
Hematology analyzers, 6/17
June 2017—Horiba has developed two new hematology systems, the Yumizen H1500 and the Yumizen H2500. The CE-marked analyzers offer a throughput of 120 tests per hour for complete blood count, including differential and nucleated red blood cells, and are equipped with a three-dimensional count capable of combining the measurements of cellular complexity, volume, and distribution for each of the leukocyte subpopulations.
FDA-approved sepsis test, 6/16
June 2017—Immunexpress received FDA 510(k) clearance for the use of SeptiCyte Lab as an aid in differentiating infection-positive (sepsis) from infection-negative (SIRS) systemic inflammation in critically ill patients on their first day of ICU admission. It is the first RNA-based clinical diagnostic tool, direct from whole blood, to aid medical providers in the early identification of infection in suspected sepsis patients, according to a company statement.
Siemens gets $8.9 million to develop Zika test, 6/17
June 2017—The U.S. Department of Health and Human Services announced that Siemens Healthineers has been awarded $8.9 million by the Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority to advance the development of a Zika assay for use on the company’s Advia Centaur XPT, Advia Centaur XP, and Advia Centaur CP immunoassay systems for the clinical laboratory.